144 related articles for article (PubMed ID: 19906851)
1. Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma.
Dennedy MC; Smith D; O'Shea D; McKenna TJ
Eur J Endocrinol; 2010 Feb; 162(2):213-20. PubMed ID: 19906851
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome.
Rachoń D
Exp Clin Endocrinol Diabetes; 2012 Apr; 120(4):205-9. PubMed ID: 22421986
[TBL] [Abstract][Full Text] [Related]
3. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women?
Kaltsas GA; Mukherjee JJ; Kola B; Isidori AM; Hanson JA; Dacie JE; Reznek R; Monson JP; Grossman AB
Clin Endocrinol (Oxf); 2003 Jul; 59(1):34-43. PubMed ID: 12807501
[TBL] [Abstract][Full Text] [Related]
4. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation].
Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U
Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992
[TBL] [Abstract][Full Text] [Related]
5. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
6. Postmenopausal hyperandrogenism.
Yoldemir T
Climacteric; 2022 Apr; 25(2):109-117. PubMed ID: 33988479
[TBL] [Abstract][Full Text] [Related]
7. Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism.
Unluhizarci K; Kaltsas G; Kelestimur F
Eur J Clin Invest; 2012 Jan; 42(1):86-94. PubMed ID: 21623779
[TBL] [Abstract][Full Text] [Related]
8. Approach to androgen excess in women: Clinical and biochemical insights.
Cussen L; McDonnell T; Bennett G; Thompson CJ; Sherlock M; O'Reilly MW
Clin Endocrinol (Oxf); 2022 Aug; 97(2):174-186. PubMed ID: 35349173
[TBL] [Abstract][Full Text] [Related]
9. Differentiating Polycystic Ovary Syndrome from Adrenal Disorders.
Yesiladali M; Yazici MGK; Attar E; Kelestimur F
Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140452
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Leydig cell tumor in a peri-menopausal woman with severe hyperandrogenism and virilization.
Nardo LG; Ray DW; Laing I; Williams C; McVey RJ; Seif MW
Gynecol Endocrinol; 2005 Oct; 21(4):238-41. PubMed ID: 16316848
[TBL] [Abstract][Full Text] [Related]
11. Hyperandrogenism in post-menopausal women: a diagnosis challenge.
Tutzer M; Winnykamien I; Davila Guardia J; Castelo-Branco C
Gynecol Endocrinol; 2014 Jan; 30(1):23-5. PubMed ID: 24188447
[TBL] [Abstract][Full Text] [Related]
12. From diagnosis to treatment of androgen-secreting ovarian tumors: a practical approach.
Rojewska P; Meczekalski B; Bala G; Luisi S; Podfigurna A
Gynecol Endocrinol; 2022 Jul; 38(7):537-542. PubMed ID: 35647677
[TBL] [Abstract][Full Text] [Related]
13. Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman.
Hirschberg AL
J Clin Endocrinol Metab; 2023 Apr; 108(5):1243-1253. PubMed ID: 36409990
[TBL] [Abstract][Full Text] [Related]
14. Hirsutism and virilism in women.
Kirschner MA
Spec Top Endocrinol Metab; 1984; 6():55-93. PubMed ID: 6084314
[TBL] [Abstract][Full Text] [Related]
15. Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis.
Mamoojee Y; Ganguri M; Taylor N; Quinton R
Clin Endocrinol (Oxf); 2018 Jan; 88(1):13-20. PubMed ID: 28980338
[TBL] [Abstract][Full Text] [Related]
16. No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours.
Pelusi C; Forlani G; Zanotti L; Gambineri A; Pasquali R
Clin Endocrinol (Oxf); 2013 Apr; 78(4):533-8. PubMed ID: 22583337
[TBL] [Abstract][Full Text] [Related]
17. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.
Kaltsas GA; Isidori AM; Kola BP; Skelly RH; Chew SL; Jenkins PJ; Monson JP; Grossman AB; Besser GM
J Clin Endocrinol Metab; 2003 Jun; 88(6):2634-43. PubMed ID: 12788867
[TBL] [Abstract][Full Text] [Related]
18. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
19. Postmenopausal hyperandrogenism: the under-recognized value of inhibins.
Shearer JL; Salmons N; Murphy DJ; Gama R
Ann Clin Biochem; 2017 Jan; 54(1):174-177. PubMed ID: 27278937
[TBL] [Abstract][Full Text] [Related]
20. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.
Barnes RB; Rosenfield RL; Ehrmann DA; Cara JF; Cuttler L; Levitsky LL; Rosenthal IM
J Clin Endocrinol Metab; 1994 Nov; 79(5):1328-33. PubMed ID: 7962325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
